Conivaptan hydrochloride | CAS#168626-94-6

MedKoo Cat#: 526637 | Name: Conivaptan hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Conivaptan hydrochloride is a non-peptide inhibitor of antidiuretic hormone (vasopressin receptor antagonist).

Chemical Structure

Conivaptan hydrochloride

CAS#168626-94-6

Theoretical Analysis

MedKoo Cat#: 526637

Name: Conivaptan hydrochloride

CAS#: 168626-94-6

Chemical Formula: C32H27ClN4O2

Exact Mass:

Molecular Weight: 535.04

Elemental Analysis: C, 71.84; H, 5.09; Cl, 6.63; N, 10.47; O, 5.98

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Conivaptan hydrochloride

IUPAC/Chemical Name

N-[4-(2-Methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide hydrochloride

InChi Key

BTYHAFSDANBVMJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C32H26N4O2.ClH/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22;/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37);1H

SMILES Code

O=C(NC1=CC=C(C(N2CCC(NC(C)=N3)=C3C4=CC=CC=C42)=O)C=C1)C5=CC=CC=C5C6=CC=CC=C6.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 535.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: García-Arroyo FE, Tapia E, Blas-Marron MG, Gonzaga G, Silverio O, Cristóbal M, Osorio H, Arellano-Buendía AS, Zazueta C, Aparicio-Trejo OE, Reyes-García JG, Pedraza-Chaverri J, Soto V, Roncal-Jiménez C, Johnson RJ, Sánchez-Lozada LG. Vasopressin Mediates the Renal Damage Induced by Limited Fructose Rehydration in Recurrently Dehydrated Rats. Int J Biol Sci. 2017 Jul 18;13(8):961-975. doi: 10.7150/ijbs.20074. eCollection 2017. PubMed PMID: 28924378; PubMed Central PMCID: PMC5599902. 2: Zeynalov E, Jones SM, Elliott JP. Therapeutic time window for conivaptan treatment against stroke-evoked brain edema and blood-brain barrier disruption in mice. PLoS One. 2017 Aug 30;12(8):e0183985. doi: 10.1371/journal.pone.0183985. eCollection 2017. PubMed PMID: 28854286; PubMed Central PMCID: PMC5576654. 3: Vinod P, Krishnappa V, Chauvin AM, Khare A, Raina R. Cardiorenal Syndrome: Role of Arginine Vasopressin and Vaptans in Heart Failure. Cardiol Res. 2017 Jun;8(3):87-95. doi: 10.14740/cr553w. Epub 2017 Jun 30. Review. PubMed PMID: 28725324; PubMed Central PMCID: PMC5505291. 4: Tuli G, Tessaris D, De Sanctis L, Matarazzo P. Tolvaptan utilization in children with chronic hyponatremia due to inappropriate antidiuretic hormone secretion (SIADH). Three case reports and review of the literature. J Clin Res Pediatr Endocrinol. 2017 May 17. doi: 10.4274/jcrpe.4531. [Epub ahead of print] PubMed PMID: 28515029. 5: Der-Nigoghossian C, Lesch C, Berger K. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients. Pharmacotherapy. 2017 May;37(5):528-534. doi: 10.1002/phar.1926. Epub 2017 Apr 17. PubMed PMID: 28295447. 6: Marbury T, Fox J, Kaelin B, Pavliv L. Pharmacokinetics of conivaptan use in patients with severe hepatic impairment. Drug Des Devel Ther. 2017 Feb 13;11:373-382. doi: 10.2147/DDDT.S125459. eCollection 2017. PubMed PMID: 28243060; PubMed Central PMCID: PMC5315214. 7: Bhandari S, Peri A, Cranston I, McCool R, Shaw A, Glanville J, Petrakova L, O'Reilly K. A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans. Clin Endocrinol (Oxf). 2017 Jun;86(6):761-771. doi: 10.1111/cen.13315. Epub 2017 Mar 27. Review. PubMed PMID: 28214374. 8: Reddy SN, Rangappa P, Jacob I, Janakiraman R, Rao K. Efficacy of conivaptan and hypertonic (3%) saline in treating hyponatremia due to syndrome of inappropriate antidiuretic hormone in a tertiary Intensive Care Unit. Indian J Crit Care Med. 2016 Dec;20(12):714-718. doi: 10.4103/0972-5229.195708. PubMed PMID: 28149029; PubMed Central PMCID: PMC5225772. 9: Zeynalov E, Jones SM, Elliott JP. Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema. J Vis Exp. 2016 Sep 1;(115). doi: 10.3791/54170. PubMed PMID: 27684044. 10: Krishnankutty SV, Rajan S. The Effect of Intravenous Conivaptan on Intraocular Pressure. J Ophthalmic Vis Res. 2016 Jan-Mar;11(1):126-7. doi: 10.4103/2008-322X.180714. PubMed PMID: 27195099; PubMed Central PMCID: PMC4860980. 11: Zeynalov E, Jones SM. Recent advances and future directions in preclinical research of arginine-vasopressin (AVP) receptor blocker conivaptan in the context of stroke. Neural Regen Res. 2016 Mar;11(3):392-3. doi: 10.4103/1673-5374.179038. PubMed PMID: 27127464; PubMed Central PMCID: PMC4828990. 12: Yang M, Orgah J, Zhu J, Fan G, Han J, Wang X, Zhang B, Zhu Y. Danhong injection attenuates cardiac injury induced by ischemic and reperfused neuronal cells through regulating arginine vasopressin expression and secretion. Brain Res. 2016 Jul 1;1642:516-523. doi: 10.1016/j.brainres.2016.04.046. Epub 2016 Apr 20. PubMed PMID: 27107944. 13: Palmer BF, Rock AD, Woodward EJ. Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics. Drug Des Devel Ther. 2016 Jan 18;10:339-51. doi: 10.2147/DDDT.S95326. eCollection 2016. PubMed PMID: 26848258; PubMed Central PMCID: PMC4723016. 14: Nakayama S, Amiry-Moghaddam M, Ottersen OP, Bhardwaj A. Conivaptan, a Selective Arginine Vasopressin V1a and V2 Receptor Antagonist Attenuates Global Cerebral Edema Following Experimental Cardiac Arrest via Perivascular Pool of Aquaporin-4. Neurocrit Care. 2016 Apr;24(2):273-82. doi: 10.1007/s12028-015-0236-4. PubMed PMID: 26732270. 15: Decker D, Collier L, Lau T, Olivera R, Roma G, Leonardo C, Seifert H, Rowe D, Pennypacker KR. The Effects of Clinically Relevant Hypertonic Saline and Conivaptan Administration on Ischemic Stroke. Acta Neurochir Suppl. 2016;121:243-50. doi: 10.1007/978-3-319-18497-5_43. PubMed PMID: 26463956. 16: Zeynalov E, Jones SM, Seo JW, Snell LD, Elliott JP. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice. PLoS One. 2015 Aug 14;10(8):e0136121. doi: 10.1371/journal.pone.0136121. eCollection 2015. PubMed PMID: 26275173; PubMed Central PMCID: PMC4537303. 17: Rajan S, Srikumar S, Paul J, Kumar L. Effectiveness of single dose conivaptan for correction of hyponatraemia in post-operative patients following major head and neck surgeries. Indian J Anaesth. 2015 Jul;59(7):416-20. doi: 10.4103/0019-5049.160943. PubMed PMID: 26257414; PubMed Central PMCID: PMC4523962. 18: Tanındı A, Töre HF. [Use of "Vaptans" in treatment of hyponatremia]. Turk Kardiyol Dern Ars. 2015 Apr;43(3):292-301. doi: 10.5543/tkda.2015.71508. Review. Turkish. PubMed PMID: 25906004. 19: Gilotra NA, Russell SD. Arginine vasopressin as a target in the treatment of acute heart failure. World J Cardiol. 2014 Dec 26;6(12):1252-61. doi: 10.4330/wjc.v6.i12.1252. Review. PubMed PMID: 25548615; PubMed Central PMCID: PMC4278160. 20: Hedna VS, Bidari S, Gubernick D, Ansari S, Satriotomo I, Khan AA, Qureshi AI. Treatment of stroke related refractory brain edema using mixed vasopressin antagonism: a case report and review of the literature. BMC Neurol. 2014 Nov 18;14:213. doi: 10.1186/s12883-014-0213-0. Review. PubMed PMID: 25403760; PubMed Central PMCID: PMC4237783.